Novo Nordisk Canada

Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease. Free trade agreements as they relate to the biopharmaceutical industry. Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Advocate for the implementation of a federal diabetes and obesity strategy. Advocate for the establishment of public-private partnerships to support chronic disease prevention.

Support the establishment of a life sciences strategy in Canada Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Advocate for the implementation of a federal diabetes and obesity strategy. Advocate for the establishment of partnerships to support chronic disease prevention.